Full results from the positive Phase III KALOS and LOGOS trials have been published in The Lancet Respiratory Medicine.

Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or ...

GSK's Nucala (mepolizumab) has received European Commission approval as an add on maintenance treatment for uncontrolled COPD. The approval is supported by positive Phase III MATINEE trial results.

FLAME analysis suggests COPD exacerbation risk spikes for 3 months after stopping LAMA or ICS, underscoring adherence and careful step-down.

AstraZeneca AZN reported fourth-quarter 2025 core earnings of $2.12 per share, which missed the Zacks Consensus Estimate of $2.18 per share. Earnings rose 1% year over year on a reported basis but ...

GSK’s Nucala receives European Commission approval to treat chronic obstructive pulmonary disease: London, UK Saturday, February 7, 2026, 09:00 Hrs [IST] GSK plc announced the E ...

Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...

Contemporary data on the availability, cost and affordability of essential medicines for chronic respiratory diseases (CRDs) across low-income and middle-income countries (LMICs) are missing, despite ...

Background: Although some meta-analyses show that triple inhaled therapy (TT) reduces all-cause mortality compared with dual inhaled therapy (DT), the effect on cardiovascular events is not yet well ...

Background: Long-acting beta-agonist (LABA) plus long-acting muscarinic antagonist (LAMA) is superior to monotherapy or corticosteroid/LABA in terms of improving lung function, alleviating symptoms ...